British National Formulary (BNF) 71

This Medical Association and Royal Pharmaceutical Society of Great Britain app-book is developed by Medhand Mobile Libraries. Improve your performance with relevant, valid material which is accessed quickly and with minimal effort in the palm of your hand using MedHand’s patented technology.

THIS APP-BOOK for BNF 71 includes unique functions such as:

• A powerful search
• Bookmarks
• Complete set of medical calculators; Body Mass Index, Peak Expiratory Flows, Dehydration Correction Calculator and more
• Highlighting
• History
• Notes and picture notes

The March 2016 British National Formulary (BNF) provides up-to-date, practical guidance on prescribing, dispensing, and administering medicines. This essential reference reflects current best practice as well as legal and professional guidelines relating to the uses of medicines.

The resource includes:

• Guidance on the drug management of common conditions
• Details of medicines prescribed within the UK with special reference to their uses, cautions, contra-indications, side-effects, doses and relative costs. This allows treatment to be tailored to the individual needs of each patient.
• Guidance on prescribing, monitoring, dispensing and adminstering medicines.

BNF 71 (March 2016) has been revised and revalidated to reflect changes in product availability, emerging safety concerns and shifts in clinical practice. Access to the latest edition of the BNF is vital for healthcare professionals, as there are a large number of updates from one edition to the next.

Some of the significant content updates for BNF 71 include:

• New safety information, including:
o very low risk of subacute cutaneous lupus erythematosus with proton pump inhibitors
o risk of severe bradycardia and heart block when hepatitis C drugs taken with amiodarone hydrochloride
o risk of diabetic ketoacidosis with sodium glucose co-transporter 2 (SGLT2) inhibitors
o increased reports of eye irritation since reformulation of latanoprost (Xalatan®)
• Updated advice for further measures to minimise risk of osteonecrosis of the jaw associated with use of denosumab and intravenous bisphosphonates
• Updated safety information on risk factors for uterine perforation associated with the use of intra-uterine contraception (intra-uterine contraceptive devices (copper) and levonorgestrel)
• Inclusion of monitoring recommendations for risks of cardiac failure with crizotinib
• Updates to immunisation schedule (Summer 2015): meningococcal group B vaccine, meningococcal groups A, C, W135 and Y vaccine, and influenza vaccine added
• Addition of new preparations including Otezla® (apremilast), Kengrexal® (cangrelor), Velphoro® (sucroferricoxyhydroxide), and more
• Significant dose changes including avanafil, colistimethate sodium (Promixin®), oseltamivir, and more


The BNF evaluates clinical evidence from diverse sources with information validated by a network of clinical experts and published under the authority of a Joint Formulary Committee.


Authors: Joint Formulary Committee

________________________________________

Important information: This app will be removed from sale when newer edition have been released.

MedHand Mobile Libraries offers a SUBSCRIPTION FREE application without edition upgrade.

MedHand has created user-friendly, quick and intuitive applications which have been honored with numerous 5 star reviews praising the interface and layout. Offering the most trusted and well recognized medical guidelines provided by excellent publishers. MedHand delivers what you need, trusted knowledge at the point of care!

MedHand are presenting latest editions from renowned publishers such as Oxford University Press, McGraw-Hill, Royal Pharmaceutical Society, PDR Network LLC, Wiley and more.